Patent: 7,674,810
✉ Email this page to a colleague
Summary for Patent: 7,674,810
| Title: | 1,1-dioxo-1H-1.LAMBDA..sup.6-benzo[d]isothiazol-3-yl)-4-hydroxy-1,5-dihydr- o-pyrrol-2-one inhibitors of HCV polymerase |
| Abstract: | Compounds having the formula i wherein m, R.sup.1, R.sup.2, R.sup.4 and X.sup.1 are herein defined are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for inhibiting hepatitis replication, processes for making the compounds and synthetic intermediates used in the process. ##STR00001## |
| Inventor(s): | Blake; James F. (Longmont, CO), Fell; Jay Bradford (Longmont, CO), Fischer; John P. (Longmont, CO), Hendricks; Robert Than (San Carlos, CA), Spencer; Stacey Renee (Lyons, CO), Stengel; Peter J. (Longmont, CO) |
| Assignee: | Roche Palo Alto LLC (Palo Alto, CA) |
| Application Number: | 11/413,872 |
| Patent Claims: | see list of patent claims |
Details for Patent 7,674,810
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Merck Sharp & Dohme Corp. | PEGINTRON | peginterferon alfa-2b | Injection | 103949 | 01/19/2001 | ⤷ Try a Trial | 2039-02-26 |
| Merck Sharp & Dohme Corp. | SYLATRON | peginterferon alfa-2b | For Injection | 103949 | 03/29/2011 | ⤷ Try a Trial | 2039-02-26 |
| Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 10/16/2002 | ⤷ Try a Trial | 2039-02-26 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
